News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy
Eric Singhi/X
Jan 29, 2025, 07:45

Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy

Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Phase 2 SKIPPirr: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemo

Oral dexamethasone 8mg BID (Day -2, -1 and 1 dose 1 h pre-infusion)
IRRs  ~3-fold (22.5% v 67.4%)
IMO practice-changing.”

Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy

Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study – Journal of Thoracic Oncology

Authors: Alexander I. Spira, Luis Paz-Ares, Ji-Youn Han, Jin-Yuan Shih, Céline Mascaux, Upal Basu Roy, Jon Zugazagoitia,  Yu Jung Kim, Chao-Hua Chiu, Sang-We Kim, Ernest Nadal, Ignacio Gil-Bazo, Sean P. Murphy, Bailey G. Anderson, Yichuan Xia, George Wang, Joshua M. Bauml, Marc Chioda, Jairo Simoes, Parthiv J. Mahadevia, Gilberto Lopes.

Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy

Alexander I. Spira Bailey G. Anderson cancer Céline Mascaux Chao-Hua Chiu Eric Singhi Ernest Nadal George Wang Gilberto Lopes Ignacio Gil-Bazo Jairo Simoes Ji-Youn Han Jin-Yuan Shih Jon Zugazagoitia Joshua M. Bauml Luis Paz-Ares Marc Chioda OncoDaily Oncology Parthiv J. Mahadevia Sang-We Kim Sean P. Murphy Upal Basu Roy Yichuan Xia Yu Jung Kim
Special Coverage
Blog
Jan 29, 2025, 07:45
Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy
Blog
Jan 29, 2025, 07:43
Pashtoon Kasi: Immunotherapy's Potential in Refractory Patients with Liver Metastases
Blog
Jan 29, 2025, 07:41
Cathy Eng: Role of ctDNA and the impact on decision making in stage II/III colon cancer disease
Blog
Jan 29, 2025, 07:39
Sharlene Gill: Practice-changing ALASCCA ph3 trial
Blog
Jan 29, 2025, 07:38
Mark Lewis: Learning the Power of Saying No
Blog
Jan 29, 2025, 07:37
Bishal Gyawali: Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Blog
Jan 29, 2025, 07:35
Petros Grivas: Inspired after interacting with so awesome colleagues at AUC3
Blog
Jan 29, 2025, 07:28
Ruzanna Papyan: SIOP Global Health Network AYA Working Group, Charlas de Café
Blog
Jan 29, 2025, 07:25
Tracey O'Brien: A series to showcase the impact of palliative care by Cancer Institute NSW
Science
Jan 29, 2025, 07:24
Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas
Blog
Jan 29, 2025, 06:21
Save the date for 43rd National Conference on Cytometry - AIEOP
Blog
Jan 28, 2025, 20:25
Hung Trinh: Direct in vivo CAR T cell engineering